New screening tests look promising in struggle to achieve the goal of a pristine blood supply
This article was originally published in Clinica
Delegates to this year's annual meeting of the American Association of Blood Banking (AABB) held in San Francisco last month discussed a number of pressing issues, including nucleic acid testing (NAT) for hepatitis C virus (HCV) and HIV and transfusion safety. Danielle Rydberg and Kerri Weinert, of Boston Biomedical Consultants in the US, report on the new products.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.